89bio Inc (NASDAQ:ETNB) has a beta value of 1.29 and has seen 0.53 million shares traded in the recent trading session. The company, currently valued at $1.03B, closed the recent trade at $7.05 per share which meant it lost -$0.22 on the day or -2.96% during that session. The ETNB stock price is -67.94% off its 52-week high price of $11.84 and 15.04% above the 52-week low of $5.99. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.72 million shares traded. The 3-month trading volume is 2.46 million shares.
The consensus among analysts is that 89bio Inc (ETNB) is Buy stock at the moment, with a recommendation rating of 1.36. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.5.
89bio Inc (NASDAQ:ETNB) trade information
Sporting -2.96% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ETNB stock price touched $7.05 or saw a rise of 24.36%. Year-to-date, 89bio Inc shares have moved -9.78%, while the 5-day performance has seen it change -11.92%. Over the past 30 days, the shares of 89bio Inc (NASDAQ:ETNB) have changed -20.55%. Short interest in the company has seen 11.01 million shares shorted with days to cover at 6.91.
Wall Street analysts have a consensus price target for the stock at $25, which means that the shares’ value could jump 71.8% from the levels at last check today. The projected low price target is $12.0 while the price target rests at a high of $29.0. In that case, then, we find that the latest price level in today’s session is -311.35% off the targeted high while a plunge would see the stock gain -70.21% from the levels at last check today.
89bio Inc (ETNB) estimates and forecasts
The company’s shares have lost -2.76% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%. If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 32.21% over the past 5 years. Earnings growth for 2025 is a modest 42.05% while over the next 5 years, the company’s earnings are expected to increase by 18.45%.
ETNB Dividends
89bio Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
89bio Inc (NASDAQ:ETNB)’s Major holders
Insiders own 1.00% of the company shares, while shares held by institutions stand at 93.49% with a share float percentage of 94.44%. Investors are also buoyed by the number of investors in a company, with 89bio Inc having a total of 225.0 institutions that hold shares in the company. The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 14.18 million shares worth more than $113.54 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 14.1994% of shares outstanding.
The other major institutional holder is JANUS HENDERSON GROUP PLC, with the holding of over 13.28 million shares as of 2024-06-30. The firm’s total holdings are worth over $106.32 million and represent 13.2986% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund. As of Dec 31, 2024, the former fund manager holds about 2.11% shares in the company for having 3.08 shares of worth $22.14 million while later fund manager owns 2.76 shares of worth $19.85 million as of Dec 31, 2024, which makes it owner of about 1.89% of company’s outstanding stock.
